In obese patients with coronary artery disease and type 2 diabetes, liraglutide with metformin reduced estimates of lipolysis compared with placebo with metformin.
In plain wordsIn obese people with heart disease and new type 2 diabetes, liraglutide with metformin lowered fat breakdown more than placebo with metformin.
- Peptide
- Liraglutide
- Outcome
- DecreaseEstimates of lipolysis
- Study
n = 41
- Comparator
- Placebo-metformin
- Outcome group
- Lipids · Metabolic and weight
- Studied dose
- Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Liraglutide-metformin reduced estimates of lipolysis.
2 context sentences(design, population, supporting numbers)
In a randomized, double-blind, placebo-controlled, cross-over trial, 41 T2DM patients with coronary artery disease were randomized and treated with liraglutide-metformin vs placebo-metformin during 12- + 12-week periods with a wash-out period of at least 2 weeks before and between the intervention periods.
NEFA kinetics were estimated using the Boston Minimal Model of NEFA metabolism, with plasma NEFA and glucose levels measured during a standard 180-minute frequently sampled intravenous glucose tolerance test.